Telomere Diagnostics, Inc. (TDx), previously known as Telome Health, Inc., announces its name change
Telomere Diagnostics, Inc. (TDx), developer of the TeloTest™ diagnostic test that measures average telomere length in human cells from a saliva sample, announces that it has changed its corporate name from Telome Health, Inc. to Telomere Diagnostics Inc. (www.telomereDx.com) This name change comes as a confirmation of the long-term strategy of the company, which is to become the global market leader in telomere-related testing for the prevention, diagnosis and management of human diseases and premature aging.
After the CLIA certification of its lab in early 2013, Telomere Diagnostics (previously known as Telome Health) has initiated a controlled launch of the Telotest™ among a small selection of physicians. It is planning to make the Telotest™ fully available to physicians in the U.S. for the wellness market in the coming months. In addition, TDx is validating additional and complementary diagnostic tests focused on Telomere Biology, in order to increase the predictive power of its existing panel.
"As we are planning to fully launch our Telotest™ in the Wellness market, this name change comes as a confirmation of our long-term commitment, which is to lead the way in the development of innovative assays based on Telomere Biology," explained TDx's interim CEO, Alexandre Le Vert. "We are working hard to complement this test with additional Telomere Biology based tests, so that we build a portfolio of strong prognostic and companion diagnostic tests going forward."
"We will leverage on our first diagnostic test, the Telotest™, to expand and build what we believe will be the most comprehensive panel of clinically and scientifically validated assays in Telomere Biology," stated TDx's Chief Scientific Officer, Calvin Harley, Ph.D.
Over 10,000 peer-reviewed scientific publications, and the 2009 Nobel Prize in Physiology or Medicine, relate to telomere biology and aging or disease. Many of these articles support the diagnostic utility of telomere-related measurements to monitor health status, disease risk, prognosis, and drug response. Some of these studies establish both associations and causal links between short telomeres or altered telomerase levels and major diseases including cancer, cardiovascular, fibrotic, inflammatory and infectious diseases, depression, and diabetes. While most biomarkers are specific for certain diseases, telomere shortness is a parameter uniquely predictive of an increased risk of many diseases. In some studies, it is superior to conventional biomarkers.
The multiple applications of telomere-based diagnostics measurement toward prevention, wellness, and individualized treatment can support a paradigm shift for healthcare.
About Telomere Diagnostics, Inc. (TDx, previously known as Telome Health, Inc.)
TDx was founded by four of the most renowned world experts in Telomere Biology, with 80 cumulative years of research in the field, more than tens of thousands of citations and a Nobel Laureate in Physiology or Medicine. TDx founders believe that telomere length as an overall index of health will be an integral component in the personalized medicine revolution, which includes individualized health maintenance plans based on new health monitoring tools.
TDx leverages the predictive power of data related to telomeres, the protective caps at the ends of chromosomes, and telomerase, the enzyme that increases the length of the telomeres, to help assess health status, disease and mortality risk, and response to specific therapies. As the field of telomere biology continues to evolve, TDx will develop and commercialize additional diagnostics based on telomere biology. The company currently provides telomere length assays in samples from academic, pharmaceutical, and corporate research groups.
For more information, go to www.telomereDx.com, www.telomerediagnostics.com – or simply www.T-Dx.com.
This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release regarding potential applications of THI's technology constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and protection of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements.
For more information, contact:
SOURCE Telomere Diagnostics, Inc.